# OnCo record atrial-fibrillation-and-bleeding-on-btk-inhibitors (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/atrial-fibrillation-and-bleeding-on-btk-inhibitors/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "atrial-fibrillation-and-bleeding-on-btk-inhibitors" ;
  schema:name "Atrial fibrillation, bleeding and high blood pressure on BTK inhibitors: assessment, monitoring and management"@en ;
  schema:alternateName "ibrutinib atrial fibrillation"@en, "BTK inhibitor cardiotoxicity"@en, "ibrutinib bleeding"@en, "stopping ibrutinib before surgery"@en, "anticoagulation on ibrutinib"@en, "acalabrutinib heart rhythm"@en, "zanubrutinib atrial fibrillation"@en, "pirtobrutinib bleeding"@en, "ibrutinib and warfarin"@en, "BTK inhibitor hypertension"@en ;
  schema:description "BTK inhibitors such as ibrutinib can cause an irregular heartbeat (atrial fibrillation), bleeding and bruising, and high blood pressure. Your team checks your pulse and blood pressure and reviews any blood thinners. The medicine may be paused around an operation or dental work. Report straight away a fast or irregular heartbeat, feeling faint, chest discomfort, or bleeding you cannot control."@en ;
  schema:url <https://onco.cc/protocols/atrial-fibrillation-and-bleeding-on-btk-inhibitors/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:tag "protocol", "cardio-oncology", "side-effect-management" ;
  onco:related <https://onco.cc/protocols/bleeding-precautions-when-platelets-are-low/>, <https://onco.cc/protocols/antithrombotic-interruption-around-surgery/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>, <https://onco.cc/protocols/hypertension-and-proteinuria-on-vegf-pathway-inhibitors/>, <https://onco.cc/protocols/anticancer-drug-interaction-review/>, <https://onco.cc/pairings/btki-ibrutinib-cardiac-caution/>, <https://onco.cc/key-papers/paper-lyon-eur-heart-j/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/pirtobrutinib/> ;
  onco:institutions <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/cardiotoxicity/> .
